Seeking Alpha

Shares of Targacept (TRGT -11%) take a hit today after the drug developer says that Phase II...

Shares of Targacept (TRGT -11%) take a hit today after the drug developer says that Phase II trials of TC-5619 - for the treatment of inattentive-predominant attention deficit/hyperactivity disorder - did not meet their primary endpoint. Quixotically, the trial results showed patients on a placebo consistently improved more than patients on TC-5619.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector